Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Choongwae develops anagliptin-metformin combo
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Dec 11, 2014 03:44:51
Choongwae starts developing a combination of a new DPP-4 inhibitor and metformin. The Ministry of Food and Drug Safety approved Choongwae’s protocol for its new combo drug which contains anagliptin and metformin.

Choongwae completed its clinical trial for anagliptin and expects anagliptin will be approved in the first half of 2015. Anagliptin has been already marketed under the brand name of Suiny in Japan.

Choongwae plans to roll out anagliptin and a combo drug of anagliptin and metformin at the almost same time, but it depends on how price negotiation goes.

Currently most of the combo drugs containing a DPP-4 inhibitor are performing well.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com